Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQT NASDAQ:HRTX NASDAQ:MDGL NASDAQ:NXTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$23.59+3.5%$22.48$12.72▼$31.77$2.95B1.511.50 million shs590,228 shsHRTXHeron Therapeutics$0.41+1.3%$0.89$0.40▼$2.30$77.61M1.582.30 million shs2.29 million shsMDGLMadrigal Pharmaceuticals$480.89+0.8%$515.19$275.00▼$615.00$11.13B-1.07335,197 shs139,502 shsNXTCNextCure$2.25-3.5%$9.05$2.17▼$15.74$8.12M1.357,647 shs79,295 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics+5.80%+9.62%+7.65%-4.84%+60.38%HRTXHeron Therapeutics-10.74%-10.02%-66.54%-58.26%-80.90%MDGLMadrigal Pharmaceuticals+2.06%+5.31%-6.50%+10.51%+70.17%NXTCNextCure-16.49%-31.47%-76.13%-82.87%-63.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$23.59+3.5%$22.48$12.72▼$31.77$2.95B1.511.50 million shs590,228 shsHRTXHeron Therapeutics$0.41+1.3%$0.89$0.40▼$2.30$77.61M1.582.30 million shs2.29 million shsMDGLMadrigal Pharmaceuticals$480.89+0.8%$515.19$275.00▼$615.00$11.13B-1.07335,197 shs139,502 shsNXTCNextCure$2.25-3.5%$9.05$2.17▼$15.74$8.12M1.357,647 shs79,295 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics+5.80%+9.62%+7.65%-4.84%+60.38%HRTXHeron Therapeutics-10.74%-10.02%-66.54%-58.26%-80.90%MDGLMadrigal Pharmaceuticals+2.06%+5.31%-6.50%+10.51%+70.17%NXTCNextCure-16.49%-31.47%-76.13%-82.87%-63.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.50Moderate Buy$34.0044.12% UpsideHRTXHeron Therapeutics 2.00Hold$2.50509.76% UpsideMDGLMadrigal Pharmaceuticals 2.78Moderate Buy$687.0042.86% UpsideNXTCNextCure 2.20Hold$23.00922.68% UpsideCurrent Analyst Ratings BreakdownLatest NXTC, ARQT, HRTX, and MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026HRTXHeron Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$2.006/2/2026HRTXHeron Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/1/2026MDGLMadrigal Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOverweight6/1/2026MDGLMadrigal Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/13/2026MDGLMadrigal Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$640.00 ➝ $709.005/11/2026HRTXHeron Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/7/2026MDGLMadrigal Pharmaceuticals EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$649.005/7/2026MDGLMadrigal Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$587.00 ➝ $578.005/7/2026ARQTArcutis Biotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.005/6/2026MDGLMadrigal Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$620.005/6/2026NXTCNextCure Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$376.07M7.85N/AN/A$1.55 per share15.22HRTXHeron Therapeutics$154.90M0.50N/AN/A$0.07 per share5.86MDGLMadrigal Pharmaceuticals$958.40M11.57N/AN/A$26.54 per share18.12NXTCNextCureN/AN/AN/AN/A$9.97 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$16.14M-$0.03N/A24.58N/A-0.57%-1.41%-0.59%8/5/2026 (Estimated)HRTXHeron Therapeutics-$20.19M-$0.18N/AN/AN/A-20.53%-7,747.30%-8.94%8/11/2026 (Estimated)MDGLMadrigal Pharmaceuticals-$288.28M-$12.80N/A56.51N/A-27.32%-50.15%-25.44%8/4/2026 (Estimated)NXTCNextCure-$55.84M-$17.19N/AN/AN/AN/A-186.96%-124.62%8/6/2026 (Estimated)Latest NXTC, ARQT, HRTX, and MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026HRTXHeron Therapeutics-$0.03-$0.04-$0.01-$0.04$36.72 million$34.71 million5/7/2026Q1 2026NXTCNextCure-$2.1050-$1.87+$0.2350-$1.87N/AN/A5/6/2026Q1 2026ARQTArcutis Biotherapeutics-$0.02-$0.09-$0.07-$0.09$103.68 million$105.40 million5/6/2026Q1 2026MDGLMadrigal Pharmaceuticals-$3.61-$3.25+$0.36-$3.25$301.05 million$311.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.542.682.46HRTXHeron Therapeutics17.512.531.51MDGLMadrigal Pharmaceuticals0.633.503.16NXTCNextCureN/A4.614.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/AHRTXHeron Therapeutics80.01%MDGLMadrigal Pharmaceuticals98.50%NXTCNextCure42.65%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%HRTXHeron Therapeutics5.86%MDGLMadrigal Pharmaceuticals17.60%NXTCNextCure11.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150125.08 million113.33 millionOptionableHRTXHeron Therapeutics300189.28 million178.19 millionOptionableMDGLMadrigal Pharmaceuticals9023.06 million19.00 millionOptionableNXTCNextCure903.61 million3.18 millionNo DataNXTC, ARQT, HRTX, and MDGL HeadlinesRecent News About These CompaniesNXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic CancersJune 4, 2026 | globenewswire.comNextCure, Inc. (NASDAQ:NXTC) Receives Consensus Rating of "Hold" from BrokeragesJune 3, 2026 | americanbankingnews.comNextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma TranscriptJune 2, 2026 | seekingalpha.comNextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026June 1, 2026 | globenewswire.comNextCure (NXTC) Stock Forecast & Price TargetMay 25, 2026 | investing.comLucid Capital Markets initiates coverage of NextCure (NXTC) with buy recommendationMay 11, 2026 | msn.comNextCure Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comNextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic CancersMay 4, 2026 | globenewswire.comNextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026April 21, 2026 | markets.businessinsider.comNextCure and Simcere Announce Presentation of Phase 1 Data for SIM0505 at ASCO 2026April 21, 2026 | quiverquant.comQNextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026April 21, 2026 | globenewswire.comNextCure Insider Trading Activity | NASDAQ:NXTC | BenzingaApril 10, 2026 | benzinga.comNextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian CancerApril 7, 2026 | globenewswire.comNextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026March 31, 2026 | markets.businessinsider.comNextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026March 31, 2026 | globenewswire.comNextCure Provides Business Update and Reports Full Year 2025 Financial ResultsMarch 5, 2026 | globenewswire.comNextCure Provides Business UpdateJanuary 23, 2026 | globenewswire.comNextCure launches at-the-market stock offering programDecember 20, 2025 | msn.comNextCure files to sell 2.52M shares of common stock for holdersNovember 26, 2025 | msn.comNextCure to Present at the Piper Sandler 37th Annual Healthcare ConferenceNovember 20, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNXTC, ARQT, HRTX, and MDGL Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$23.59 +0.80 (+3.52%) As of 01:37 PM Eastern This is a fair market value price provided by Massive. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Heron Therapeutics NASDAQ:HRTX$0.41 +0.01 (+1.26%) As of 01:37 PM Eastern This is a fair market value price provided by Massive. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Madrigal Pharmaceuticals NASDAQ:MDGL$480.89 +4.00 (+0.84%) As of 01:37 PM Eastern This is a fair market value price provided by Massive. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.NextCure NASDAQ:NXTC$2.25 -0.08 (-3.48%) As of 01:36 PM Eastern This is a fair market value price provided by Massive. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FuelCell Energy Just Got a Wake-Up Call From Wall Street Uranium Energy Corp Melts Down—Nuclear Opportunity at Hand Corning Is Paving AI's Future With Glass Short Sellers Are Piling Into Wingstop, But Analysts See Big Upside Optical Cable Corporation: Strong Earnings, But Hurdles Remain The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
